clinical research

Welcoming NIH’s Four Newest Lasker Scholars

IRP Program Boosts Careers of Promising Physician-Scientists

clockwise from top-left: Dr. Lisa McReynolds, Dr. Chris Grunseich, Dr. Samira Sadowski, and Dr. Andrea Lisco

Many scientists have a seemingly single-minded focus on their research, but there are considerable benefits to having one foot in the lab and the other in the clinic. Working with patients gives researchers a daily reminder of the people they are working so hard to help and allows them to investigate the effects of promising but still experimental treatments in willing volunteers. That’s one of the main reasons why the IRP’s Lasker Clinical Research Scholars Program is designed to accelerate the careers of promising early-career physician-scientists. 

This year, four NIH researchers began receiving support from the Lasker program, allowing them to dramatically expand their cutting-edge research. From investigating the roots of muscle-weakening genetic conditions to probing the mysteries of rare, hormone-producing tumors, these individuals will use the leg up provided by the Lasker Program to make new discoveries that could one day improve their patients’ lives. Read on to learn more about the exciting research the latest crop of Lasker Scholars is pursuing.

NIH Mourns the Passing of John Gallin

Dr. John Gallin

NIH Director Monica M. Bertagnolli, M.D., offered the following tribute to Dr. John I. Gallin, M.D., upon hearing of his passing on Thursday, October 10, 2024.

It is with a heavy heart that I share that John I. Gallin, M.D., the 10th and longest-serving director of the NIH Clinical Center, died at his home today of multiple myeloma at the age of 81 with his wife Elaine Gallin, Ph.D., by his side.

John’s illustrious career at NIH spanned more than 50 years, but he will be most remembered for leading NIH’s research hospital for 23 years from 1994-2017. He often said that his time at the NIH Clinical Center, which he referred to as the “House of Hope,” was his most special because of the hospital’s partnership with patients to improve health through clinical research. He developed the hospital’s research portfolio, created the Patient Advisory Group, established the Department of Bioethics, and was instrumental in the creation of the Edmond J. Safra Family Lodge for adult patients and their families, a complement to The Children’s Inn. He also led efforts to build the addition to the hospital, the Mark O. Hatfield Clinical Research Center, which opened to patients in 2005. He started the Bench-to-Bedside Awards to integrate the work of basic and clinical investigators. His years of work led to the NIH Clinical Center receiving the 2011 Lasker-Bloomberg Public Service Award.

Applying Rare Disease Discoveries to Diabetes

Patients With Rare Metabolic Conditions Yield Insights Into Common Ailments

overweight patient talking with doctor

Young doctors are taught the adage, “When you hear hoofbeats, think horses, not zebras.” Just as you would not expect to find a zebra in your barn, when making a diagnosis, you generally don’t expect to find an unusual disease. However, just as there are still zebras in the world, there are also rare diseases. On Rare Disease Day, celebrated on the last day of February each year, we call attention to the 300 million people affected by them.

Defined as conditions that affect fewer than 1 in 2,000 people, rare diseases pose both challenges and opportunities to medical research. Because they are so uncommon, diagnosis can take years, and treatments may be difficult to obtain or may not yet exist. However, for IRP Lasker Clinical Research Scholar Rebecca J. Brown, M.D., M.H.Sc., the study of several rare metabolic diseases may shed light on the causes of one of the most common diseases in the U.S.

IRP Research Yields Life-Changing Treatments

Highlighting Drugs and Vaccines Stemming from NIH Discoveries

syringe and vials of medicine

On May 3, more than six decades of IRP research culminated in the U.S. Food and Drug Administration (FDA) approving the world’s first vaccine for respiratory syncytial virus (RSV), a disease that puts tens of thousands of Americans in the hospital each year and kills thousands. While the new vaccine, called Arexy, has been getting all the headlines recently, it is only the latest example of a slew of FDA-approved medications and vaccines that might never have existed without the tireless efforts of scientists at NIH.

Indeed, a recently published study led by Mark Rohrbaugh, Ph.D., J.D., a special advisor in the NIH Office of Science Policy, found that inventions developed at NIH have contributed to more FDA-approved products than those created at any other nonprofit research institution in the world over the past five decades. NIH tops the study’s list with 27 FDA-approved products, six more than the study attributed to the combined efforts of all the schools in the University of California system.

Sugar Molecule Could Resolve Rare Diseases

IRP Research Hastens Development of First Treatment for Genetic Muscle Condition

cartoon highlighting one person in a crowd

An old medical adage warns doctors that when they hear hoofbeats, they should first think of horses, not zebras. After all, when someone comes into the hospital with a cough, the most likely explanation is something mundane like the flu. However, some patients truly are medical zebras, affected by a disease that afflicts very few others.

IRP senior investigator Marjan Huizing, Ph.D., has learned quite a bit about those zebras since arriving at the National Human Genome Research Institute (NHGRI) as a postdoctoral fellow in 1998. To help commemorate Rare Disease Day today, Dr. Huizing spoke with the “I Am Intramural” blog about her research on an array of ailments linked to a small sugar molecule called sialic acid, some of which are extremely rare.

Postdoc Profile: From Bench to Bedside and Back Again

Dr. Stefan Barisic Turns Laboratory Discoveries into Kidney Cancer Treatments

Dr. Stefan Barisic

The Laboratory of Transplantation Immunotherapy sits at the heart of the NIH Clinical Center, just down the hallway from the Southeast inpatient unit. Here, IRP postdoctoral research fellow Stefan Barisic, M.D., labors at the bench with the goal of creating practical treatments for kidney cancer patients. Having such proximity to his patients was one of the chief attractions of working at NIH for Dr. Barisic.

“The NIH Clinical Center is an amazing place because it has all the resources you need to go from the bench to the bedside and back to the bench all in one building,” says Dr. Barisic.